News
News GlobeNewswire NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations ...
Perhaps it’s just the summer slowdown, but it’s been a light month for executive hires in the pharma and biotech world.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results